QNCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quince Therapeutics Inc (QNCX) is not a good buy for a long-term beginner investor with $50,000-$100,000 available for investment. The company has faced significant setbacks, including the discontinuation of its primary asset, negative financial performance, and overwhelmingly bearish analyst sentiment. The lack of positive catalysts and trading signals further supports a sell recommendation.
The MACD is positive at 0.165, showing slight bullish momentum, but it is contracting. RSI is neutral at 54.92, indicating no clear signal. Moving averages are converging, suggesting indecision in price direction. Key support and resistance levels are Pivot: 1.329, R1: 1.488, S1: 1.17, R2: 1.586, S2: 1.072. Overall, the technical indicators do not provide a strong buy signal.
NULL identified.
The company's estimated cash and debt levels are approximately equal, indicating financial instability.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$39.46M (up 216.73% YoY), and an EPS of -1.68 (up 500% YoY). Gross margin remains at 0%. The financials indicate poor performance with no signs of recovery.
Analysts have overwhelmingly downgraded the stock. D. Boral Capital, Maxim, Lucid Capital, and Citizens have all issued downgrades, citing the failure of the Phase 3 trial and the lack of value in the company's shares. Lucid Capital has set a price target of $0, reflecting a complete loss of confidence in the stock.
